TWM537906U - Compound particle structure - Google Patents
Compound particle structure Download PDFInfo
- Publication number
- TWM537906U TWM537906U TW105210736U TW105210736U TWM537906U TW M537906 U TWM537906 U TW M537906U TW 105210736 U TW105210736 U TW 105210736U TW 105210736 U TW105210736 U TW 105210736U TW M537906 U TWM537906 U TW M537906U
- Authority
- TW
- Taiwan
- Prior art keywords
- sweet potato
- core
- potato protein
- starch
- green banana
- Prior art date
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
Description
本創作為一種紅藷蛋白與綠蕉澱粉之健康複合物微粒結構,可用於減重、調節血糖、增加腸道益生菌等用途。 The present invention is a healthy composite particle structure of sweet potato protein and green banana starch, which can be used for weight loss, regulating blood sugar, and increasing intestinal probiotics.
健康是每個人都應該重視的事情,但時常因為忙碌生活而疏於照顧使得許多健康問題造成生活的困擾。肥胖以及腸道的健康的失衡都會大大提升罹患疾病的風險。 Health is something that everyone should pay attention to, but often taking care of it because of busy life makes many health problems cause life problems. Obesity and the imbalance of intestinal health can greatly increase the risk of disease.
控制肥胖的方法很多,其原理不外乎是減少熱量攝取或增加熱量消耗。減少熱量攝取可以藉由食用低熱量食物或高飽足感食物來達到目的,市面上常見的產品是膳食纖維,其能在消化系統中吸收水分,使得食物體積增加,造成飽足感。而增加熱量消耗除了運動之外也有些產品,如:辣椒素、共軛亞麻油酸能在服用後提升人體新陳代謝速率達到消耗熱量的效果。 There are many ways to control obesity, the principle is nothing more than reducing calorie intake or increasing calorie expenditure. Reducing calorie intake can be achieved by eating low-calorie foods or high-satisfaction foods. The most common product on the market is dietary fiber, which absorbs water in the digestive system, increasing the volume of food and causing satiety. In addition to exercise, there are also some products, such as capsaicin and conjugated linoleic acid, which can increase the body's metabolic rate and consume calories after taking it.
大、小腸是人體主要吸收養分的器官,在腸道中存在許多微生物會幫助消化和養分吸收,但營養不均衡容易造成腸道中菌相失衡,造成益生菌減少,可能引發腸道疾病、發炎甚至是癌症。目前市面上有許多改善腸道健康的產品,其中以乳酸菌為大宗,多為飲品方式服用。 The large and small intestines are the organs that the body mainly absorbs nutrients. Many microorganisms in the intestines will help digestion and nutrient absorption. However, the imbalance of nutrition may cause the imbalance of the bacteria in the intestinal tract, resulting in the reduction of probiotics, which may cause intestinal diseases, inflammation or even cancer. There are many products on the market that improve the health of the intestines. Among them, lactic acid bacteria are the bulk, and most of them are taken by drinks.
但市面上產品仍存在些缺點,膳食纖維有以飲品或是添加於 食物中的方式使用,飲品有產品攜帶、開封後要盡速使用完的保存問題,而添加進食品中則有口感不佳的情形;而乳酸菌產品以飲品為主,且多須冷藏保存,否則容易失去活性。故目前市面上商品有攜帶便利不佳、口感不好以及保存不便的問題,而且市面上並沒有同時兼具減重效果又兼顧腸胃道健康又沒有口感以及保存困難之產品,本創作即有此特性,能帶給大眾更為便利就能獲得促進健康的功效。 However, there are still some shortcomings in the market. Dietary fiber has a drink or added to it. The way in which the food is used, the beverage has the product to be carried, the storage problem to be used as soon as possible after opening, and the food is added to the food, the taste is not good; and the lactic acid bacteria product is mainly based on drinks, and more must be refrigerated, otherwise Easy to lose activity. Therefore, at present, the products on the market have problems of poor carrying convenience, poor taste and inconvenient storage, and there is no product on the market that has both weight-reducing effects and gastrointestinal health and no taste and storage difficulties. Characteristics, can bring more convenience to the public to achieve health promotion.
為了減少大眾攝取此類營養補充品的不便,並且在能在減重時也兼顧腸道健康,本創作提供一種複合物微粒結構,其以紅藷蛋白或綠蕉澱粉為芯體,再包裹有效性成分層於芯體外圍,並於有效性成分層之外再以保護層包覆。紅藷蛋白係包含胰蛋白酶抑制劑(Trypsin Inhibitor,TI)與醣蛋白,易於被腸道吸收,可達到增加飽足感、調節血脂與促進新陳代謝的功效。綠蕉澱粉含有高量的抗解澱粉(Resistant Starch,RS),在大腸中經微生物發酵能產生短鏈脂肪酸、增加益菌數量以保護大腸細胞健康。該複合物微粒結構之粒徑係介於120μm至500μm之間,芯體厚度介於30μm至150μm之間,該有效性成分層之厚度係介於20μm至70μm之間。 In order to reduce the inconvenience of the public to take such nutritional supplements, and also to take into account the intestinal health in weight loss, this creation provides a composite particle structure, which uses sweet potato protein or green banana starch as the core, and then package the effectiveness. The component layer is on the periphery of the core and is covered with a protective layer in addition to the effective component layer. The sweet potato protein system contains Trypsin Inhibitor (TI) and glycoprotein, which is easily absorbed by the intestine and can increase satiety, regulate blood lipids and promote metabolism. The green banana starch contains a high amount of Resistant Starch (RS), which can produce short-chain fatty acids in the large intestine and increase the number of beneficial bacteria to protect the health of the large intestine cells. The particle structure of the composite is between 120 μm and 500 μm, the core thickness is between 30 μm and 150 μm , and the thickness of the effective component layer is between 20 μm and 70 μm . between.
較佳是,有效性成分層包含以下至少一種成分:綠蕉澱粉、紅藷蛋白、柑橘(Citrus)萃取物、益生菌及其任意組合。較佳是,綠蕉澱粉不同時出現在芯體和有效性成分層中。較佳是,紅藷蛋白不同時出現在芯體和有效性成分層中。較佳是,芯體包含綠蕉澱粉和紅藷蛋白的其中一種,而有效性成分層包含另外一種。該有效性成分層之成分具有如下功能:有 助於增加飽足感、抑制食慾、提升抗氧化能力、促進新陳代謝、增加腸道益生菌、控制血糖等。 Preferably, the effectiveness component layer comprises at least one of the following components: plantain starch, sweet potato protein, Citrus extract, probiotics, and any combination thereof. Preferably, the green banana starch does not simultaneously appear in the core and the active ingredient layer. Preferably, the sweet potato protein does not simultaneously appear in the core and the active ingredient layer. Preferably, the core comprises one of green banana starch and sweet potato protein, and the active ingredient layer comprises the other. The components of the effectiveness component layer have the following functions: Helps increase satiety, suppress appetite, increase antioxidant capacity, promote metabolism, increase intestinal probiotics, and control blood sugar.
本創作之一較佳實例中,該複合物微粒結構係作為一保健食品或一醫藥品;其可填充入膠囊或作為錠劑之形式。 In a preferred embodiment of the present invention, the composite particulate structure is used as a health food or a pharmaceutical product; it can be filled into a capsule or in the form of a tablet.
本創作之一較佳實例中,該複合物微粒結構係可填充入粉包。 In a preferred embodiment of the present invention, the composite particulate structure can be filled into a powder packet.
本創作之功效除可提供飽足感外,同時具有抑制食慾、調節血糖血脂、加速脂肪分解及促進新陳代謝、增加腸道益生菌以及保護腸道健康之功效。同時本創作之複合物微粒結構同時兼具減重及改善腸道健康之特性,並不具有膳食纖維產品口感不佳以及乳酸菌產品保存不易、攜帶不便的缺點。創作人開發出兼具減重及改善腸道健康兩者功能之產品,能使一般大眾能更直接與便利之方式得到保健之效果。 In addition to providing a feeling of satiety, the effect of this creation has the effects of suppressing appetite, regulating blood sugar and blood fat, accelerating fat decomposition and promoting metabolism, increasing intestinal probiotics and protecting intestinal health. At the same time, the composite particle structure of the present invention has the characteristics of reducing weight and improving intestinal health, and has the disadvantages of poor taste of the dietary fiber product and difficulty in storage and inconvenience of the lactic acid bacteria product. The creator has developed a product that combines both weight loss and improved intestinal health, enabling the general public to get health care in a more direct and convenient way.
本創作所提供具有減重以及改善腸道健康功能之健康複合物微粒結構可達到減輕體重、降低體脂肪、增加飽足感、降低血脂、降低血糖、改善胰島素感受性(Insulin sensibility)、改善腸道健康、增加腸道益生菌、以及預防癌症等多重功效。 The creation of a healthy complex microparticle structure with weight loss and improved intestinal health functions can reduce body weight, reduce body fat, increase satiety, lower blood fat, lower blood sugar, improve insulin sensitivity (Insulin sensibility), and improve intestinal tract. Multiple effects such as health, increased intestinal probiotics, and cancer prevention.
1‧‧‧健康複合物微粒結構 1‧‧‧Health Composite Particle Structure
10‧‧‧保護層 10‧‧‧Protective layer
20‧‧‧有效性成分層 20‧‧‧ Effective ingredient layer
30‧‧‧芯體 30‧‧‧ core
40‧‧‧膠囊體 40‧‧‧Capsule body
50‧‧‧凹槽 50‧‧‧ Groove
60‧‧‧粉包 60‧‧‧Powder
70‧‧‧切口 70‧‧‧ incision
80‧‧‧錠劑基底 80‧‧‧Plate base
90‧‧‧錠劑 90‧‧‧Lozenges
第一圖係為本創作之一較佳實例之健康複合物微粒結構之剖面示意圖;第二圖係為本創作之一較佳實例之健康複合物微粒結構填充於一膠囊體內之立體剖面圖;第三圖係為本創作之一較佳實例之健康複合物微粒結構之粉包之示意圖; 第四圖係為本創作之一較佳實例之健康複合物微粒結構製成錠劑之示意圖。 The first figure is a schematic cross-sectional view of a healthy composite particle structure according to a preferred example of the present invention; the second figure is a perspective sectional view of a healthy composite particle structure of a preferred embodiment of the present invention filled in a capsule; The third figure is a schematic view of a powder package of a healthy composite particle structure according to a preferred embodiment of the present invention; The fourth figure is a schematic diagram of a tablet made from a healthy composite particle structure of a preferred embodiment of the present invention.
本創作係提供一種具有減重以及促進腸道健康之健康複合物微粒結構。為完整且清楚地揭露本創作之技術內容目的功效,茲於下列詳細說明,並參閱第一圖所示,係顯示本創作健康複合物微粒結構之一實施例的剖面示意圖。本實例係選擇球體做為示意圖,但不以此為限。本創作之健康複合物微粒結構1,係包含一保護層10,一有效性成分層20及包含紅藷蛋白或綠蕉澱粉的芯體30。前述紅藷蛋白係利用特殊技術萃取純化之蛋白,其含有天然的胰蛋白酶抑制劑與醣蛋白,可達到增加飽足感、調節血脂與促進新陳代謝的功效。前述澱粉係利用特殊技術提煉出的澱粉,其含有高量的抗解澱粉,在大腸中經微生物發酵能產生短鏈脂肪酸、增加益菌數量以保護大腸細胞健康。 This creation provides a healthy complex particle structure that reduces weight and promotes intestinal health. For a complete and clear disclosure of the efficacies of the technical content of the present invention, the following detailed description, and reference to the first figure, is a schematic cross-sectional view showing one embodiment of the present invention. In this example, the sphere is selected as a schematic diagram, but not limited thereto. The present invention relates to a healthy composite particulate structure 1 comprising a protective layer 10, a effectiveness component layer 20 and a core 30 comprising sweet potato protein or green banana starch. The aforementioned sweet potato protein is extracted and purified by a special technique, which contains natural trypsin inhibitor and glycoprotein, which can increase the feeling of satiety, regulate blood lipids and promote metabolism. The starch is a starch extracted by a special technique, which contains a high amount of anti-gelatinized starch, and can be produced by microbial fermentation in the large intestine to produce short-chain fatty acids and increase the number of beneficial bacteria to protect the health of the large intestine cells.
本創作係提供一種具有減重以及促進腸道健康之健康複合物微粒結構1,微粒結構之粒徑係介於120μm至500μm之間,由紅藷蛋白或綠蕉澱粉組成的芯體30的厚度介於30μm至150μm之間,該有效性成分層20之厚度係介於20μm至70μm之間。 This creation provides a healthy composite microparticle structure with weight loss and intestinal health promotion. The particle size of the microparticle structure is between 120 μm and 500 μm . The core consists of sweet potato protein or green banana starch. The thickness of 30 is between 30 μm and 150 μm , and the thickness of the effectiveness component layer 20 is between 20 μm and 70 μm .
紅薯,又稱為地瓜、白薯、甘藷、蕃薯等,係為一旋花科一年生植物,係一種藥食兼用的健康食品。紅薯含有膳食纖維、胡蘿蔔素、維生素A、B、C、E及鉀、鐵、銅、硒、鈣等10餘種微量元素,營養價值很高,稱之為營養最均衡的保健食品。 Sweet potato, also known as sweet potato, sweet potato, sweet potato, sweet potato, etc., is an annual plant of the genus Asteraceae, a healthy food for both medicine and food. Sweet potato contains dietary fiber, carotene, vitamin A, B, C, E and more than 10 kinds of trace elements such as potassium, iron, copper, selenium and calcium. It has high nutritional value and is called the most balanced health food.
本創作之紅藷蛋白能刺激小腸分泌膽囊收縮素(Cholecystokinin,CCK),將飽足訊號傳遞至大腦的下視丘,故在服用後可增加飽足感,有效減少進食量。紅藷蛋白亦能夠影響脂肪細胞的增生與分化,造成脂肪細胞減少,達到降低脂肪的效果。 The sweet potato protein of this creation can stimulate the small intestine to secrete cholecystokinin (CCK), and transmit the satiety signal to the hypothalamus of the brain, so it can increase the satiety after taking it and effectively reduce the food intake. Sweet potato protein can also affect the proliferation and differentiation of fat cells, resulting in the reduction of fat cells and the effect of reducing fat.
綠蕉澱粉是經創作人特殊萃取技術提煉出的超純度澱粉,其含有50%以上的天然抗解澱粉。綠蕉澱粉能抵抗小腸中澱粉分解脢的作用而不被分解,而在大腸中經微生物發酵產生短鏈脂肪酸,其中包含乙酸(Acetate)、丙酸(Propionate)、丁酸(Butyrate)。綠蕉澱粉能使腸道微生物數量大大增加,且腸道益生菌的量依不同種類有數十至百倍的提升。短鏈脂肪酸的量能提升12%,其中丁酸更提高了28%。短鏈脂肪酸是許多腸道益生菌的養分,特別是丁酸,丁酸是大腸上皮細胞之主要養分來源,抗解澱粉能使大上皮細胞有充足的養分,減少細胞突變發生,能有預防大腸癌之功效。故綠蕉澱粉有增進腸道健康及預防癌症之效果。 The green banana starch is an ultra-purity starch extracted by the creator's special extraction technology, which contains more than 50% of natural anti-gelatinized starch. The banana banana starch can resist the decomposition of the starch in the small intestine without being decomposed, and is microbially fermented in the large intestine to produce short-chain fatty acids, including Acetate, Propionate, and Butyrate. The green banana starch can greatly increase the number of intestinal microbes, and the amount of probiotics in the intestine increases tens to 100 times depending on the species. The amount of short-chain fatty acids can be increased by 12%, and butyric acid is increased by 28%. Short-chain fatty acids are the nutrients of many intestinal probiotics, especially butyric acid, which is the main source of nutrients for large intestinal epithelial cells. Anti-mycorrhizal starch can make large epithelial cells have sufficient nutrients, reduce cell mutation, and prevent colon in the large intestine. The effect of cancer. Therefore, the green banana starch has the effect of improving intestinal health and preventing cancer.
本創作之健康複合物微粒結構1其中含紅藷蛋白或綠蕉澱粉之芯體30之紅藷蛋白與綠蕉澱粉均由特殊製程提煉而成。紅藷蛋白製程如下:先將紅藷洗淨去皮放入研磨機中研磨成泥,再以均質機將紅藷分子顆粒達到微粒效果;將紅藷微粒置於冰箱,加入1~5%乙酸(使pH值達到4)及1%至10%氯化鈉萃取出胰蛋白酶抑制劑;再利用離心機(轉速1,500rpm至2,500rpm)將紅藷微粒中之紅藷沉澱物與紅藷液分離,取出紅藷液(其含所需之胰蛋白酶抑制劑以及醣蛋白);之後,利用加溫設備將紅藷液加熱至72~80度,將胰蛋白酶抑制劑之外成分去除,再使用冰桶降溫至20至25度;利用過濾 膜將紅藷液中微小分子去除;利用微濾薄膜去除紅藷液中較大分子量之有機分子,以選取具有20至200KD分子量之目標蛋白質之紅藷萃取物,最後將所得之萃取物以真空冷凍乾燥法乾燥,以保存其生物活性。 The healthy composite microparticle structure of the present invention 1 wherein the sweet potato protein and the green banana starch containing the sweet potato protein or the green banana starch core 30 are all made by a special process. The process of sweet potato protein is as follows: firstly wash and peel the sweet potato into the grinder and grind it into mud, then use the homogenizer to achieve the particle effect of the sweet potato molecular particles; place the sweet potato particles in the refrigerator and add 1~5% acetic acid (to make the pH value) 4) and 1% to 10% sodium chloride were extracted from the trypsin inhibitor; the sweet potato pellet in the sweet potato microparticles was separated from the sweet potato liquid by a centrifuge (rpm 1,500 rpm to 2,500 rpm), and the sweet potato liquid was taken out (including The desired trypsin inhibitor and glycoprotein); after that, the sweet potato liquid is heated to 72-80 degrees by heating equipment, the components other than the trypsin inhibitor are removed, and then the ice bucket is used to cool to 20 to 25 degrees; filter The membrane removes the tiny molecules in the sweet potato liquid; the organic molecules of the larger molecular weight in the sweet potato liquid are removed by the microfiltration membrane to select the sweet potato extract of the target protein having a molecular weight of 20 to 200 KD, and finally the obtained extract is vacuum freeze-dried. Dry to preserve its biological activity.
本創作之健康複合物微粒結構1其中含紅藷蛋白或綠蕉澱粉之芯體30之紅藷蛋白與綠蕉澱粉均由特殊製程提煉而成。綠蕉澱粉製程如下:將未成熟之香蕉剝皮、切塊,再與0.05至0.25N NaOH一同放入均質機中一同攪拌破碎並靜置4~12小時。將溶液通過篩網後利用離心將澱粉沉澱於底部,再取出烘乾。 The healthy composite microparticle structure of the present invention 1 wherein the sweet potato protein and the green banana starch containing the sweet potato protein or the green banana starch core 30 are all made by a special process. The process of the green banana starch is as follows: the immature banana is peeled and diced, and then placed in a homogenizer together with 0.05 to 0.25 N NaOH, stirred and allowed to stand for 4 to 12 hours. After passing the solution through the sieve, the starch was precipitated at the bottom by centrifugation, and then taken out and dried.
本創作之健康複合物微粒結構1其中該有效性成分層20係包含以下至少一種成分:綠蕉澱粉、紅藷蛋白、柑橘萃取物、益生菌及上述的任意組合。根據本創作一較佳實施例,當芯體30包含紅藷蛋白時,有效性成分層20係選自以下所組成之群組的至少其中之一:綠蕉澱粉、柑橘萃取物、益生菌及其任意組合。根據本創作一較佳實施例,當芯體30包含綠蕉澱粉時,有效性成分層20係選自以下所組成之群組的至少其中之一:紅藷蛋白、柑橘萃取物、益生菌及其任意組合。該有效性成分層20之成分具有以下功能:有助於增加飽足感、抑制食慾、提升抗氧化能力、促進新陳代謝、增加腸道益生菌、控制血糖與預防癌症等。 The present invention relates to a healthy composite particulate structure 1 wherein the effectiveness component layer 20 comprises at least one of the following components: green banana starch, sweet potato protein, citrus extract, probiotics, and any combination thereof. According to a preferred embodiment of the present invention, when the core 30 comprises sweet potato protein, the effective component layer 20 is selected from at least one of the group consisting of: banana leaf starch, citrus extract, probiotics and random combination. According to a preferred embodiment of the present invention, when the core 30 comprises the green banana starch, the effective component layer 20 is selected from at least one of the group consisting of sweet potato protein, citrus extract, probiotics and random combination. The component of the active ingredient layer 20 has the following functions: it helps to increase satiety, suppress appetite, enhance antioxidant capacity, promote metabolism, increase intestinal probiotics, control blood sugar, and prevent cancer.
柑橘萃取物係由金桔、扁實檸檬與檸檬全果提煉萃取而成,含有類黃酮(flavonoid)、維生素C、川陳皮素(Nobilatin)……..等,有提升抗氧化力、控制血糖等效果。 The citrus extract is extracted from the whole fruit of kumquat, flat lemon and lemon. It contains flavonoids, vitamin C, Nobilatin, etc., which enhances antioxidant power and controls blood sugar. And so on.
益生菌係包含比菲德氏菌(Bifidobacterium bifidum)、雷特氏 B菌(Bifidobacterium lactis)、嗜酸乳桿菌(Lactobacillus acidophilus)、洛德乳桿菌(Lactobacillus reuteri)、Eubacterium rectale、Eubacterium ramulus、Roseburia cecicola等至少其中之一。益生菌可以促進消化、降低腸道過敏反應、提升免疫力及增加丁酸產生等效果。 Probiotics contain Bifidobacterium bifidum, Reiter At least one of B bacteria (Bifidobacterium lactis), Lactobacillus acidophilus, Lactobacillus reuteri, Eubacterium rectale, Eubacterium ramulus, Roseburia cecicola, and the like. Probiotics can promote digestion, reduce intestinal allergic reactions, improve immunity and increase the production of butyric acid.
本創作之一實例中該健康複合物微粒結構總量為1500mg,其中芯體為紅藷蛋白且有效性成分層為綠蕉澱粉,相對於總重量,紅藷蛋白約佔整體10%以上及綠蕉澱粉約佔整體80%。 In one example of the present invention, the total amount of the healthy composite microparticle structure is 1500 mg, wherein the core is sweet potato protein and the effective component layer is green banana starch, and the sweet potato protein accounts for about 10% or more of the total banana starch starch relative to the total weight. About 80% of the total.
本創作又一實例中該健康複合物微粒結構總量為1500mg,其中芯體為綠蕉澱粉且有效性成分層為紅藷蛋白,相對於總重量,綠蕉澱粉約佔整體80%,而紅藷蛋白約佔整體10%以上。 In another example of the present invention, the total amount of the healthy composite microparticle structure is 1500 mg, wherein the core is a green banana starch and the effective component layer is sweet potato protein, and the green banana starch accounts for about 80% of the total weight, and the sweet potato protein is compared with the total weight. About 10% of the total.
本創作又一實例中該健康複合物微粒結構總量為1500mg,其中芯體為綠蕉澱粉且有效性成分層含有紅藷蛋白和益生菌,相對於總重量,綠蕉澱粉約佔整體80%,且紅藷蛋白和益生菌分別佔整體約10%和6%以上。 In another example of the creation, the total amount of the healthy composite microparticle structure is 1500 mg, wherein the core is a green banana starch and the effective component layer contains sweet potato protein and probiotic bacteria, and the green banana starch accounts for about 80% of the total weight. And sweet potato protein and probiotics account for about 10% and 6% of the total, respectively.
本創作又一實例中該健康複合物微粒結構總量為1500mg,其中芯體為綠蕉澱粉且有效性成分層含有益生菌和柑橘萃取物,相對於總重量,綠蕉澱粉約佔整體80%,且益生菌和柑橘萃取物分別佔整體約6%和10%以上。 In another example of the present invention, the total amount of the healthy composite microparticle structure is 1500 mg, wherein the core is a green banana starch and the effective component layer contains probiotic bacteria and citrus extract, and the green banana starch accounts for about 80% of the total weight relative to the total weight. And probiotics and citrus extracts account for about 6% and more than 10% of the total.
本創作之又一實例中該健康複合物微粒結構總量為1500mg,其中芯體為紅藷蛋白且有效性成分層含有綠蕉澱粉、益生菌和柑橘萃取物。相對於總量1500mg為100%而言,紅藷蛋白為約10%以上、綠蕉澱粉 為50%、益生菌為6%、柑橘萃取物為10%以上。 In yet another example of the present invention, the total amount of the fine structure of the healthy composite is 1500 mg, wherein the core is sweet potato protein and the effective ingredient layer contains green banana starch, probiotics and citrus extract. Compared with the total amount of 1500mg, 100%, the sweet potato protein is about 10% or more, and the green banana starch It is 50%, 6% for probiotics, and 10% or more for citrus extract.
以本創作之健康複合物微粒結構對40隻12週齡之Sprague-Dawley大鼠進行為期八週之動物試驗,實驗動物平均分為正常對照組(ND)、高熱量組(HE)、低劑量處理組(L-HE,紅藷綠蕉健康複合物A)、中劑量處理組(M-HE,紅藷綠蕉健康複合物B)、高劑量處理組(H-HE,紅藷綠蕉健康複合物C)、低劑量加菌組(L-HE+,紅藷綠蕉健康複合物A+)、中劑量加菌組(M-HE+,紅藷綠蕉健康複合物B+)、高劑量加菌組(H-HE+,紅藷綠蕉健康複合物C+)等八組(表一)。試驗物質(即表一中的紅藷綠蕉健康複合物)是以紅藷為芯體,綠蕉澱粉為有效性成分層,紅藷蛋白與綠蕉澱粉的比例如表一所示。加菌組之試驗物質的芯體為紅藷蛋白;有效性成分層為綠蕉澱粉加上總重量之6%的Bifidobacterium spp.與Eubacterium spp.等量混合乾燥粉末,紅藷蛋白與綠蕉澱粉的比例如表一所示。試驗動物連續投予試驗物(475mg/kg/day)八週後進行功效指標分析以及安全性指標分析。 Four 12-week-old Sprague-Dawley rats were subjected to an eight-week animal test using the healthy composite particle structure of the present invention. The experimental animals were divided into normal control group (ND), high calorie group (HE), and low dose. Treatment group (L-HE, sweet potato and green banana health complex A), medium dose treatment group (M-HE, sweet potato and green banana health complex B), high dose treatment group (H-HE, sweet potato and green banana health complex C ), low-dose plus bacteria group (L-HE+, sweet potato and green banana health complex A+), medium-dose plus bacteria group (M-HE+, sweet potato and green banana health complex B+), high-dose plus bacteria group (H-HE+, Eight groups of sweet potato green banana health complex C+) (Table 1). The test substance (ie, the sweet potato green banana health complex in Table 1) is a sweet potato core, and the green banana starch is a useful component layer, and the ratio of sweet potato protein to the green banana starch is shown in Table 1. The core of the test substance of the added bacteria group is sweet potato protein; the effective component layer is the green banana starch plus 6% of the total weight of Bifidobacterium spp. and Eubacterium spp. The same amount of dry powder, the ratio of sweet potato protein to the banana starch As shown in Table 1. The test animals were continuously administered the test substance (475 mg/kg/day) for eight weeks, and the efficacy index analysis and the safety index analysis were performed.
功效指標測量方法 Efficacy indicator measurement method
誘發動物肥胖:試驗動物除了正常對照組之外,皆餵食高熱量食物(HED),並以餵食HED後體重高於正常對照組20%以上為誘導成功之依據。試驗動物餵食HED後六週成功誘發肥胖。 Induced animal obesity: In addition to the normal control group, the test animals were fed with high-calorie food (HED), and the body weight after feeding HED was higher than 20% of the normal control group as the basis for the induction success. The test animals successfully induced obesity six weeks after feeding HED.
體重:試驗期間每周定期測量試驗動物體重,並比較試驗開始時與結束之體重。 Body weight: The body weight of the test animals was measured periodically every week during the test, and the weight at the beginning and end of the test was compared.
攝食量:每日記錄各試驗動物隻飼料攝取量。 Food intake: The feed intake of each test animal was recorded daily.
體脂肪種與體指率:動物犧牲時,取出腹腔內脂肪(腹腔膜內之副睪(epididymis)附近、腎臟周圍及腸膜上之脂肪)秤重。作為體脂肪重。體脂肪率為[體脂肪重(g)/體重(g)]*100%。 Body fat and body rate: When the animal is sacrificed, the fat in the abdominal cavity (the fat in the vicinity of the epidural (epididymis), around the kidney and on the intestinal membrane) is weighed. As body fat is heavy. The body fat percentage is [body fat weight (g) / body weight (g)] * 100%.
血液採集:試驗動物犧牲前禁食12小時後,以二氧化碳麻醉,收集腹腔靜脈血液,離心後取上清液(血清)進行分析。並以全自動血清分析儀(Automated biochemistry analyzer,Vitros 5.1 FS,Johnson & Johnson,Inc.,USA)分析以下項目: Blood collection: The test animals were fasted for 12 hours before sacrifice, anesthetized with carbon dioxide, and the abdominal venous blood was collected. After centrifugation, the supernatant (serum) was taken for analysis. The following items were analyzed using a fully automated serum analyzer (Vitros 5.1 FS, Johnson & Johnson, Inc., USA):
A血糖 A blood sugar
B血脂:總膽固醇(TC)、低密度膽固醇(LDL-C)、高密度膽固醇(HDL-C)、三酸甘油酯(TG)、非酯化游離脂肪酸(FFA) B blood lipids: total cholesterol (TC), low density cholesterol (LDL-C), high density cholesterol (HDL-C), triglyceride (TG), non-esterified free fatty acid (FFA)
C肝功能測試:AST、ALT C liver function test: AST, ALT
D腎功能測試:尿酸(UA)、肌酸(CRE) D renal function test: uric acid (UA), creatine (CRE)
E電解質平衡狀態:檢測血液中鈉(Na)、鉀(K)濃度 E electrolyte balance state: detection of sodium (Na) and potassium (K) concentrations in blood
F血液中酮體濃度 F blood ketone body concentration
腸道內益菌量:動物犧牲之後取出盲腸抽取DNA,利用qPCR測試腸道內Lactobacillus sps.、Bifidobacterium sps.與Clostridium cluster XIVa+b的量,以SYBR® Green qPCR試劑(assay)於ABI Prism 7900HT序列檢測系統(Applied Biosystems,Foster City,CA)中進行分析。 Intestinal Bacterial Amount: The animal was sacrificed and the cecum was taken out to extract DNA. The amount of Lactobacillus sps., Bifidobacterium sps. and Clostridium cluster XIVa+b in the intestine was tested by qPCR, and SYBR® Green qPCR reagent (assay) was used in ABI Prism 7900HT. Analysis was performed in a sequence detection system (Applied Biosystems, Foster City, CA).
功能性指標估計結果 Functional indicator estimation result
動物觀察及體重:試驗動物於試驗期間,活動狀況以及反應皆無明顯異常。試驗期間每週測量體重一次,結果顯示不論是何種處理,各組合試驗動物之體重皆有下降的趨勢。試驗結束時相較於高熱量組(HE)之體重,M-HE、H-HE、M-HE+與H-HE+各組的試驗動物體重均有顯著降低。體脂肪量與體脂率均有相同的狀況(表二)。 Animal observation and body weight: There were no significant abnormalities in the activity and response of the test animals during the test. The body weight was measured once a week during the test, and the results showed that the body weight of each of the combined test animals showed a tendency to decrease regardless of the treatment. At the end of the experiment, the body weight of the M-HE, H-HE, M-HE+ and H-HE+ groups was significantly lower than that of the high calorie group (HE). Both the body fat mass and the body fat percentage have the same condition (Table 2).
攝食量:於處理組與對照組間沒有顯著差異。 Food intake: There was no significant difference between the treatment group and the control group.
體脂肪量與體脂肪率:動物犧牲後,取出腹腔內之脂肪進行秤重,結果顯示正常對照組(ND)的脂肪重顯著低於其他組別。高熱量對照組(HE)的脂肪量與體脂率都顯著高於其他所有處理組,體脂率高熱量對照組(HE)亦是顯著高於其他處理組(表二)。 Body fat mass and body fat percentage: After the animal sacrificed, the fat in the abdominal cavity was taken out for weighing, and the results showed that the fat weight of the normal control group (ND) was significantly lower than that of the other groups. The fat mass and body fat percentage of the high-calorie control group (HE) were significantly higher than those of all other treatment groups, and the high-fat rate of the caloric control group (HE) was also significantly higher than that of the other treatment groups (Table 2).
益菌量:益菌數是以Lactobacillus spp.、Bifidobacterium spp.與Clostridium cluster XIVa+b作為指標,除了L-HE之外其他處理組均顯著高於正常對照組(ND)以及高熱量對照組(HE),有加入益生菌的處理組相較於未加入益菌的處理組在益菌量都有顯著的提升(表三)。 The amount of beneficial bacteria: Lactobacillus spp., Bifidobacterium spp. and Clostridium cluster XIVa+b were used as indicators. The treatment groups except L-HE were significantly higher than the normal control group (ND) and the high-calorie control group ( HE), there was a significant increase in the amount of beneficial bacteria in the treatment group with the addition of probiotics compared to the treatment group without the addition of the beneficial bacteria (Table 3).
安全性指標評估結果:安全性指標評估結果顯示實驗大鼠經八週投予試驗物質後,腎功能、肝功能、血中酮體、電解質平衡、血糖與非酯化游離脂肪酸等指標均無發現異常。 Safety index evaluation results: The safety index evaluation results showed that the experimental rats were not found in renal function, liver function, blood ketone body, electrolyte balance, blood glucose and non-esterified free fatty acids after eight weeks of administration of test substances. abnormal.
血脂:血脂中總膽固醇(TC)與總三酸甘油酯(TG)高熱量對照組與其他處理組存在顯著差異,而各處理組之間無差異。而高密度膽固醇(HDL-C)各組間均無差異。低密度膽固醇(LDL-C)僅有低劑量組(L-ME)及低劑量加菌組(L-ME+)與對照組有顯著差異,其餘處理組效應均不存在(表四)。結果表示試驗物質能有效降低試驗動物血液中總膽固醇、三酸甘油酯與低密度膽固醇。 Blood lipids: Total cholesterol (TC) and total triglyceride (TG) in the blood lipids were significantly different from the other treatment groups, and there was no difference between the treatment groups. There was no difference between the groups of high-density cholesterol (HDL-C). Low-density cholesterol (LDL-C) was only significantly different between the low-dose group (L-ME) and the low-dose group (L-ME+) compared with the control group, and the other treatment groups did not exist (Table 4). The results indicate that the test substance is effective in reducing total cholesterol, triglyceride and low density cholesterol in the blood of the test animals.
試驗物質對於體重、體脂肪、體脂率與血脂均有下降的功能,對於腸道益菌數有促進之效果。綜合各種處理組合效果,中劑量加菌組(M-HE)有較佳之綜合效果。 The test substance has a function of lowering body weight, body fat, body fat percentage and blood lipid, and has an effect of promoting the number of beneficial bacteria in the intestine. In combination with various treatment combinations, the medium dose plus bacteria group (M-HE) has a better combined effect.
以下描述根據本創作之一實例的健康複合物微粒結構之製造過程,該健康複合物微粒結構由內而外為綠蕉澱粉的芯體30、有效性成分層20以及保護層10。取500g綠蕉澱粉,加入10%之阿拉伯膠作為賦形劑後,放入自動成錠機壓縮成錠。再經粉碎機調整細度為70目粉碎成粒後通過80目之篩網使綠蕉澱粉芯體粒徑一致。將該過篩後之綠蕉澱粉芯體與100g有效性成分層原料加入研發型噴霧、乾燥、造粒、膜衣機,以側噴式噴霧造粒方式,噴灑賦形劑於芯體表面,並依序包裹上有效性成分層20以及保護層10而完成健康複合物微粒結構。根據上述的製程,本領域技術人員稍加修飾即可製造出其他本創作提及的各種實施例的健康複合物微粒結構,例如表一中提及的各種健康複合物微粒結構。 The manufacturing process of the healthy composite particulate structure according to an example of the present invention is described below, which is a core body 30 of green banana starch, a layer of the active ingredient 20, and a protective layer 10 from the inside out. 500 g of plantain starch was taken, 10% gum arabic was added as an excipient, and then placed in an automatic tableting machine to be compressed into an ingot. After the pulverizer was adjusted to a fineness of 70 mesh, the granules were granulated and passed through an 80-mesh sieve to make the particle size of the green banana starch core uniform. The sieved green banana starch core and 100 g of the effective component layer raw materials are added to a research and development spray, drying, granulating and film coating machine, and sprayed on the surface of the core by side spray spray granulation, and The active ingredient layer 20 and the protective layer 10 are sequentially wrapped to complete the healthy composite particle structure. Other healthy compound particle structures of the various embodiments mentioned herein, such as the various health complex particle structures mentioned in Table 1, can be made by those skilled in the art in light of the above-described procedures.
根據本創作之一較佳實例,該保護層10係選自可供人體食用之明膠、阿拉伯膠、玉米糖膠、黃耆膠等膠狀物質。根據本創作之另一實施例,該保護層10進一步包含一賦形劑,其中該賦形劑係選自由調味劑、增甜劑、防腐劑、抗氧化劑、螯合劑、滲透劑、潤滑劑、著色劑以及結合劑組成之群體。 According to a preferred embodiment of the present invention, the protective layer 10 is selected from gelatinous substances such as gelatin, gum arabic, corn syrup, and tragacanth which are available for human consumption. According to another embodiment of the present invention, the protective layer 10 further comprises an excipient, wherein the excipient is selected from the group consisting of a flavoring agent, a sweetener, a preservative, an antioxidant, a chelating agent, a penetrating agent, a lubricant, A group of colorants and binders.
根據本創作之另一實例,該保護層10係藉由使用膜衣(film coat)而加工為一膜衣保護層;該膜衣保護層包括:糖衣、持續釋放型膜衣、 腸溶型膜衣、透明水溶性膜衣、黃色膜衣等其中一項或多項;使得當本創作之健康複合物微粒結構為口服錠劑型時,遇水之後仍能保持表面之光滑度,防止使用者吞服時沾黏於口腔或食道,並減少對腸胃的刺激。 According to another example of the present invention, the protective layer 10 is processed into a film protective layer by using a film coat; the film protective layer includes: a sugar coating, a sustained release film coat, One or more of an enteric film coat, a transparent water-soluble film coat, a yellow film coat, etc.; so that when the healthy composite particle structure of the present invention is an oral tablet type, the smoothness of the surface can be maintained after the water is prevented, preventing When swallowed, the user sticks to the mouth or esophagus and reduces irritation to the stomach.
依據前述實施例,當該保護層10係為一透明水溶性膜衣時,其成分包含如:纖維素聚合物,例如:羥丙基纖維素、羥丙基甲基纖維素、羥乙基纖維素、甲基羥乙基纖維素;合成聚合物,例如聚乙烯醇縮乙醛二乙胺基乙酯、胺基烷基甲基丙烯酸酯共聚物E、聚乙烯吡咯啶酮等;多糖,例如聚三葡萄糖等等。 According to the foregoing embodiment, when the protective layer 10 is a transparent water-soluble film coat, the components thereof include, for example, a cellulose polymer such as hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose. , methyl hydroxyethyl cellulose; synthetic polymers, such as polyvinyl acetal diethylamine ethyl ester, amino alkyl methacrylate copolymer E, polyvinylpyrrolidone, etc.; polysaccharides, for example Polytriglucose and so on.
根據本創作之一較佳實例,該保護層10係為腸溶膜衣,該腸溶型膜衣須至腸道之環境中才溶解,並將成分釋放,使活性成分免於胃酸之分解破壞。該腸溶型膜衣之組成係包含如蓖麻油、蟲膠、礦物油、丙二醇、聚甲基丙基酸酯、檸檬酸三乙酯、檸檬酸三丁指、鄰苯二甲酸二甲酯、鄰苯二甲基二乙酯、聚乙二醇、鄰苯二甲醋酸纖維素、羫丙基鄰苯二甲酸甲基纖維素、羫丙基甲基纖維素琥珀酸醋酸鹽等其中一項或多項。 According to a preferred embodiment of the present invention, the protective layer 10 is an enteric film coating which dissolves in the environment of the intestine and releases the ingredients to protect the active ingredient from decomposition and decomposition of gastric acid. . The composition of the enteric-coated film coat comprises, for example, castor oil, shellac, mineral oil, propylene glycol, polymethyl propyl ester, triethyl citrate, tributyl citrate, dimethyl phthalate, Ethyl phthalate, polyethylene glycol, cellulose phthalate, methyl propyl propyl phthalate, propyl propyl cellulose succinate acetate, or the like Multiple.
本創作所提供具有減重以及促進腸道健康之健康複合物微粒結構,係由該保護層10將含有紅藷蛋白或綠蕉澱粉之芯體30及有效性成分層20之活性成分完全包覆,以防止外界之汙染而變質,同時能具有延長並保存紅藷蛋白之活性成分的功效。再者藉由該保護層10能保護紅藷蛋白之活性成分不受身體腸胃道內消化液之破壞,具有有效幫助快速吸收之功效。 The present invention provides a healthy composite microparticle structure having weight loss and promoting intestinal health, and the protective layer 10 completely encapsulates the active ingredient of the core 30 containing the sweet potato protein or the green banana starch and the active ingredient layer 20, It can be deteriorated to prevent external pollution, and at the same time, it can have the effect of prolonging and preserving the active ingredient of sweet potato protein. Furthermore, the protective layer 10 can protect the active ingredient of the sweet potato protein from the digestive juice in the gastrointestinal tract of the body, and has the effect of effectively helping rapid absorption.
本創作之一較佳實施例中,該健康複合物微粒結構可填充入 膠囊之形式。如第二圖所示,一對膠囊體40係由可食用等級之膠質原料製成,該對膠囊體40分別呈內凹狀而形成有凹槽50,且該對膠囊體40係可以凹槽50之開口相互蓋合。本創作之該健康複合物微粒結構1可裝設於膠囊體40內。 In a preferred embodiment of the present invention, the healthy composite particle structure can be filled The form of the capsule. As shown in the second figure, a pair of capsule bodies 40 are made of an edible grade of gelatinous material, the pair of capsule bodies 40 are respectively concavely formed with grooves 50, and the pair of capsule bodies 40 can be grooved. The openings of 50 are covered with each other. The healthy composite particulate structure 1 of the present invention can be installed in the capsule body 40.
本創作之一較佳實例中,該健康複合物微粒結構1可直接由口腔攝食。如第三圖所示,該健康複合物微粒結構1可製成粉包50,食用者可由切口70撕開即可直接服用本創作包含一保護層10、一有效性成分層20及一含紅藷蛋白或綠蕉澱粉之芯體30的健康複合物微粒結構1,可方便使用。該粉包中可根據475mg/kg/day的基礎包含人體一天所需量的健康複合物微粒結構。 In a preferred embodiment of the present invention, the healthy composite particulate structure 1 can be directly ingested by the oral cavity. As shown in the third figure, the healthy composite particle structure 1 can be made into a powder package 50, and the consumer can be directly taken by the incision 70. The present invention comprises a protective layer 10, a layer of the active ingredient 20 and a sweet potato. The healthy composite microparticle structure 1 of the protein or amarylose core 30 can be conveniently used. The powder pack can contain a healthy complex particle structure required by the human body for one day according to the basis of 475 mg/kg/day.
本創作之一較佳實例中,可添加乳糖、澱粉或纖維素、含檸檬酸或蘋果酸及碳酸氫鈉之發泡成分或緩釋成分等錠劑基底,以加壓方式打成錠劑,如製成雙層錠、發泡錠、緩釋錠等。如第四圖所示,複數個健康複合物微粒結構1均勻散佈於錠劑基底80而製成錠劑90,該錠劑可做為保健食品或醫藥品。 In a preferred embodiment of the present invention, a tablet base such as lactose, starch or cellulose, a foaming component or a sustained-release component containing citric acid or malic acid and sodium hydrogencarbonate may be added, and the tablet may be formed into a tablet by pressurization. Such as double-layer ingots, foamed ingots, slow-release ingots, and the like. As shown in the fourth figure, a plurality of healthy composite fine particle structures 1 are uniformly dispersed on the tablet base 80 to form a tablet 90 which can be used as a health food or a pharmaceutical.
本創作之一較佳實例中,受試者每天早上於進食前三十分鐘空腹服用一次如第二圖所示之粉包,持續45天至60天後,受試者在體重、食量、腹部脂肪及膽固醇各方面都有明顯的改善。 In one preferred embodiment of the present invention, the subject takes an empty packet as shown in the second figure 30 minutes before eating each morning, for 45 to 60 days after the subject is in weight, food intake, and abdomen. There are significant improvements in all aspects of fat and cholesterol.
以上所述者僅為用以解釋本創作之較佳實施例,並非企圖據以對本創作做任何形式上之限制,是以,凡有在相同之創作精神下所作有關本創作之任何修飾或變更,皆仍應包括在本創作意圖保護之範疇。 The above description is only for the purpose of explaining the preferred embodiment of the present invention, and is not intended to impose any form of limitation on the creation, so that any modification or alteration of the creation made in the same creative spirit is provided. , should still be included in the scope of protection of this creative intent.
1‧‧‧健康複合物微粒結構 1‧‧‧Health Composite Particle Structure
10‧‧‧保護層 10‧‧‧Protective layer
20‧‧‧有效性成分層 20‧‧‧ Effective ingredient layer
30‧‧‧芯體 30‧‧‧ core
Claims (10)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW105210736U TWM537906U (en) | 2016-07-15 | 2016-07-15 | Compound particle structure |
CN201621111449.6U CN206950368U (en) | 2016-07-15 | 2016-10-11 | Composite particle structure for losing weight, reducing blood fat and improving intestinal health |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW105210736U TWM537906U (en) | 2016-07-15 | 2016-07-15 | Compound particle structure |
Publications (1)
Publication Number | Publication Date |
---|---|
TWM537906U true TWM537906U (en) | 2017-03-11 |
Family
ID=58775503
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW105210736U TWM537906U (en) | 2016-07-15 | 2016-07-15 | Compound particle structure |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN206950368U (en) |
TW (1) | TWM537906U (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108902593A (en) * | 2018-06-12 | 2018-11-30 | 金果园老农(北京)食品股份有限公司 | A kind of tartary buckwheat clear beverage and preparation method thereof |
-
2016
- 2016-07-15 TW TW105210736U patent/TWM537906U/en not_active IP Right Cessation
- 2016-10-11 CN CN201621111449.6U patent/CN206950368U/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN206950368U (en) | 2018-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105146614B (en) | A kind of functional calcium fruit ferment, enzyme beverage and its production method | |
CA2740434C (en) | Probiotic compositions and methods for inducing and supporting weight loss | |
JP5923238B2 (en) | Vagus nerve activator | |
Vodnar et al. | A new generation of probiotic functional beverages using bioactive compounds from agro-industrial waste | |
JP6684966B2 (en) | Novel Lactobacillus sakei and composition containing the same | |
CN109451727A (en) | The composition and its preparation and application of probiotics and digestive ferment | |
WO2014169563A1 (en) | Fruit and vegetable product for curing oral ulcer, and preparation method therefor | |
Meybodi et al. | Probiotic supplements and food products: a comparative approach | |
JP2016520305A (en) | Association of Lactonospirae bacteria and body weight in gastrointestinal microbiota | |
CN113499401A (en) | Pharmaceutical composition for treating Alzheimer disease and preparation method and application thereof | |
CN108968037A (en) | Senile dementia full nutrition formula food | |
CN106858577A (en) | Prepare the fermentation composition and preparation method of the plant enzyme with liver protecting, the fatty subtotal hepatectomy of regulation | |
CN114145461B (en) | Probiotic composition for relieving nonalcoholic fatty liver | |
WO2024149132A1 (en) | Probiotic protein multivitamin and preparation method therefor | |
TW201623626A (en) | Lactic acid bacterium having purine body uptake ability, and use thereof | |
TWI426915B (en) | Use of djulis in manufacturing of drugs for treating hyperlipidemia and hypercholesterolemia and a composition thereof | |
Kryuchkova et al. | Vegetable ingredients in functional fermented milk products | |
CN108523123A (en) | A kind of full nutritional support food of diabetes | |
CN115053929B (en) | Formula milk powder suitable for fatty liver people and preparation thereof | |
TWM537906U (en) | Compound particle structure | |
JP2007126365A (en) | Antiallergic agent comprising culture of lactobacillus plantarum as active ingredient | |
JP2001224330A (en) | Food comprising lactobacillus symbiotic culture product and medicinal plant and method for producing the same | |
CN104839657A (en) | Medical formula food for phthisis | |
CN112219903A (en) | Body-shaping and qi-tonifying milk powder for women and preparation method thereof | |
CN110200119A (en) | A kind of compound lactobacillus goat milk piece pressed candy and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4K | Annulment or lapse of a utility model due to non-payment of fees |